SAGA Diagnostics Announces NeoCircle Publication Demonstrating the Prognostic Value of ctDNA Dynamics in Early Breast Cancer
NeoCircle: pre- and post-operative circulating tumor DNA dynamics predicts survival in neoadjuvant-treated early breast cancer
SAGA Diagnostics to Present Data on Ultrasensitive Pathlight™ MRD Test in Breast, Colon, and Rectal Cancers at ASCO 2026
Key poster presentations highlight the expanding body of evidence supporting Pathlight™, SAGA’s tumor-informed structural variant (SV)-based circulating tumor DNA (ctDNA) platform, across both metastatic and localized settings.
Serial ctDNA monitoring in metastatic breast cancer using an ultrasensitive tumor-informed structural variant-based assay
Tumor-informed circulating tumor DNA identifies high-grade serous ovarian cancer patients at highest risk for recurrence despite optimal first-line treatment with primary macroscopic complete resection
SAGA Diagnostics to Present New Pathlight™ MRD Data for Ovarian and Metastatic Breast Cancer at AACR 2026
Studies across all breast-cancer subtypes confirm Pathlight’s ultra-sensitive performance for early recurrence detection and treatment-response monitoring
Foundation Medicine to Strengthen Monitoring Portfolio with SAGA Diagnostics’ Tumor-Informed Molecular Residual Disease (MRD) Platform
Pathlight, a personalized, tumor-informed molecular residual disease (MRD) platform, will expand Foundation Medicine’s testing capabilities